Artikel in diesem Bereich werden auf Englisch angezeigt.
Trade-News-Ticker, 2026-10-19: Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27 (RTTNews) - Propanc Biopharma Inc. (PPCB), a biopharmaceutical company, on… Primärquelle: Original bei Nasdaq Market Structure (nasdaq.com).
Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27
(RTTNews) - Propanc Biopharma Inc. (PPCB), a biopharmaceutical company, on Friday announced preclinical data for a formulation of pancreatic pro-enzymes (PRP) in treating pancreatic and ovarian cancer.
